Rafael Holdings Inc. is a burgeoning enterprise that has piqued the interest of investors across the globe due to its savvy investments in clinical and early stage pharmaceutical companies, as well as prime commercial real estate assets in both the United States and Israel. The firm operates under two umbrella segments, Healthcare and Real Estate, leveling up on its focus on drug development and the commercialization of therapies that exploit the metabolic differences between normal and cancerous cells. Rafael Holdings is currently at the cusp of a major breakthrough with its lead drug candidate, CPI-613 (devimistat), which has entered Phase III clinical study for metastatic pancreatic cancer and acute myeloid leukemia treatment. The company was incorporated in 2017, with its headquarters situated in the bustling city of Newark, New Jersey.
Rafael's ticker is RFL
The company's shares trade on the NYSE stock exchange
They are based in Newark, New Jersey
There are 11-50 employees working at Rafael
It is rafaelholdings.com
Rafael is in the Healthcare sector
Rafael is in the Biotechnology industry
The following five companies are Rafael's industry peers: